Altogether, these data may contribute to explain, at least in part, the poorer clinical performance of stromal inhibitors targeting the, i.e., ACTA2 and Hedgehog pathways in PDAC preclinical trials in which reduction in tumor stroma was associated with poorer responses and increased tumor progression rates [102,103]. The gene discussed is ACTA2; the disease is neoplasm.